Pfizer CEO: AI will help with medicine's next big breakthrough
View original at finance.yahoo.comPfizer CEO: AI will help with medicine's next big breakthrough Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical giant is bright…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
President Trump is more experienced in managing government in his second term and very determined
80% confidencePfizer will build manufacturing capacity for Metsera products in the US to provide US patients with US-produced anti-obesity drugs
80% confidenceAI will have a profound impact on medicine, with current capabilities exceeding what most companies are utilizing
80% confidenceMany medicines are dependent on China but Pfizer has no dependency - doesn't export from China or import anything from China to the US
80% confidenceBourla found collaboration with Kennedy very productive in many areas, including the HHS agreements announced at White House
80% confidenceIf a leader's defining characteristic is optimism, Bourla believes his is on the very high end of the spectrum
80% confidencePfizer has 11 manufacturing sites and 2 gigantic logistics centers (13 total) in the US, mostly in the South and Midwest
80% confidencePfizer's leading position will be in oncology in the near future, and will also play to be a leader in obesity
80% confidenceAI can help with target identification to find sites of cancer cells that create resistance to medicines and cause metastasis
80% confidencePfizer's two lead obesity assets failed one after the other about a year ago
80% confidenceConsumer drug prices on average are double the prices Pfizer charges in the US
80% confidenceThe acquisition's value depends on whether it works - if it works, it's worth the investment big time; if not, they overpaid
80% confidenceTrump is a disruptor who changes things people thought couldn't be changed
80% confidencePfizer has the right to win in the obesity space due to expertise in primary care, large-scale trials, manufacturing at scale, and top-ranked field force
80% confidenceBobby Kennedy would not have been Bourla's choice for HHS secretary, but he tries to work constructively
80% confidenceThe big discrepancy between affluent countries and the US in drug pricing was provocative and not sustainable
80% confidenceMetsera's oral peptides are well-formulated and don't require taking on empty stomach
80% confidenceAI can design medicines and molecules that fit targets much faster and better than traditional methods
80% confidenceBourla's optimism comes from his mother, a Holocaust survivor who emphasized that nothing is impossible
80% confidenceThe key challenge with AI is integrating it into business processes and operations, which creates anxiety and resistance
80% confidenceU.S. consumers pay for medicines as if they don't have insurance although they do, unlike hospital or MRI costs
80% confidencePfizer products from Metsera acquisition should hit market by 2028 if they move fast
80% confidenceAnimal testing for safety can be replaced in silico with AI models that accurately predict molecule behavior in toxicology and pharmacodynamics
80% confidencePfizer's primary care field force has been ranked number one consecutively for the last 10 years in the US
80% confidenceBourla and Kennedy have very big disagreements on vaccines and some scientific FDA approaches
80% confidencePfizer committed to invest $70 billion in the US over the next 3-5 years
80% confidenceVaccines will not go back to pre-Pasteur times long-term because vaccines have saved the world and are the most cost-effective medical intervention
80% confidenceMetsera has a monthly GLP-1 product and no one else is as advanced in monthly GLP-1
80% confidencePfizer plans to invest significantly to win in obesity space, following comprehensive and deep development plan
80% confidenceDrug pricing changes should be implemented beginning of the year 2026
80% confidence